Nispomeben (NRD.E1, NRD135S.E1) is a nonopioid, orally available small molecule with potential for painful diabetic peripheral neuropathy (PDPN), NRD.E1 is hypothesised to be through modulation of the phosphorylation of Lyn tyrosine kinase.
Nispomeben (NRD.E1, NRD135S.E1) has shown dose‐dependent anti‐nociceptive effects in several rodent models for both acute and chronic pain, including streptozotocin‐induced diabetic neuropathy, Chung's spinal nerve ligation, tail flick, hot plate and formalin injection.
Nispomeben (NRD.E1, NRD135S.E1) is hypothesised to be through modulation of the phosphorylation of Lyn tyrosine kinase, a critical step in the mediation of nerve injury‐induced P2X4 receptor upregulation in neuropathic pain.
Nispomeben (NRD.E1, NRD135S.E1) does not appear to act directly through any of the mechanisms, receptors, enzymes or channels known to be associated with pain and abuse‐liability, including opioid receptors.